NCT04303169 · Interventional trial
Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)
Overall registry status Completed
Phase 1 · Phase 2
Conditions Melanoma
Delaware Valley sites
- University of Pennsylvania Abramson Cancer Center ( Site 3008) · Philadelphia, PA · Philadelphia County
First posted
Registry updated
Added to the directory